Exclusive: Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidney

Nava Therapeutics discloses it has raised $89M as it targets in vivo CAR-T and kidney delivery with novel lipid nanoparticles.

Raccontata daendpoints.news